Last $19.81 USD
Change Today +0.32 / 1.64%
Volume 248.4K
VIVO On Other Exchanges
As of 8:10 PM 02/26/15 All times are local (Market data is delayed by at least 15 minutes).

meridian bioscience inc (VIVO) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/21/14 - $23.13
52 Week Low
01/2/15 - $15.56
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

meridian bioscience inc (VIVO) Related Bloomberg News

View More Bloomberg News

meridian bioscience inc (VIVO) Related Businessweek News

No Related Businessweek News Found

meridian bioscience inc (VIVO) Details

Meridian Bioscience Inc., an integrated life science company, manufactures, develops, sells, and distributes diagnostic test kits. These are used primarily for respiratory, gastrointestinal, viral, and parasitic infectious diseases. It also makes and distributes bulk antigens, antibodies, and reagents used by researchers and other diagnostic manufacturers. In addition, it contract-manufactures proteins and other biologicals for biopharmaceutical and biotechnology companies researching new drugs and vaccines. Its products and technologies are marketed to hospitals, reference labs, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in about 60 countries. Meridian, founded in 1976, is based in Cincinnati.

550 Employees
Last Reported Date: 12/1/14
Founded in 1976

meridian bioscience inc (VIVO) Top Compensated Officers

Chairman of The Board, Chief Executive Office...
Total Annual Compensation: $602.9K
Chief Financial Officer, Executive Vice Presi...
Total Annual Compensation: $263.3K
Executive Vice President of Operations and In...
Total Annual Compensation: $408.9K
President of Meridian Bioscience Europe and M...
Total Annual Compensation: $356.7K
Executive Vice President and President of Mer...
Total Annual Compensation: $307.0K
Compensation as of Fiscal Year 2014.

meridian bioscience inc (VIVO) Key Developments

Meridian Bioscience Declares Regular Quarterly Cash Dividend for the First Quarter Ended December 31, 2014, Payable on February 13, 2015

The Board of Directors of Meridian Bioscience, Inc. declared the regular quarterly cash dividend of $0.20 per share for the first quarter ended December 31, 2014. The dividend is of record February 2, 2015 and payable on February 13, 2015. This annual indicated dividend rate of $0.80 per share remains the same as the rate in fiscal 2014.

Meridian Bioscience, Inc. Announces Unaudited Earnings Results for the First Quarter Ended December 31, 2014; Reaffirms Earnings Guidance for the Fiscal Year Ending September 30, 2015

Meridian Bioscience, Inc. announced unaudited earnings results for the first quarter ended December 31, 2014. For the quarter, the company reported net revenues $48,013,000 against $44,794,000 a year ago. Operating income was $12,669,000 against $11,626,000 a year ago. Earnings before income taxes were $12,093,000 against $11,410,000 a year ago. Net earnings were $7,901,000 or $0.19 per diluted share against $7,426,000 or $0.18 per diluted share a year ago. The company re-affirmed earnings guidance for the fiscal year ending September 30, 2015, the company expects net revenues to be in the range of $193 million to $200 million and per share diluted earnings to be between $0.85 and $0.91. The per share estimates assume an increase in average diluted shares outstanding from approximately 41.9 million at fiscal 2014 year end to approximately 42.4 million at fiscal 2015 year end. The revenue and earnings guidance provided in this press release is from expected internal growth and does not include the impact of any acquisitions the Company might complete during fiscal 2015.

Meridian Bioscience Opens Office in China

Meridian Bioscience has opened an office in China. The Beijing office will be staffed by about three local people who will be new hires of Meridian Life Science Inc., a wholly owned subsidiary. Meridian has established relationships with major in vitro diagnostic companies in China by providing antigens, antibodies and blockers for in vitro commercial assays. The office on Chang-An Avenue is on the 15th floor in the New China Life Insurance Tower Center, which is in central business district and close to Tiananmen Square and government offices.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VIVO:US $19.81 USD +0.32

VIVO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ERBA Diagnostics Inc $3.45 USD +0.02
Great Basin Scientific Inc $2.67 USD +0.1199
Luminex Corp $15.97 USD -0.24
Nanosphere Inc $0.29 USD +0.0002
Quidel Corp $26.01 USD +0.33
View Industry Companies

Industry Analysis


Industry Average

Valuation VIVO Industry Range
Price/Earnings 23.2x
Price/Sales 4.3x
Price/Book 5.1x
Price/Cash Flow 23.1x
TEV/Sales 4.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MERIDIAN BIOSCIENCE INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at